Sanofi announced the opening of a new innovation and operation centre in Chengdu, a southwestern Chinese city, on March 19, 2026. The facility expands the company’s research and development capabilities and supports its manufacturing operations in the region.
The new centre builds on a €66 million investment in a global R&D hub in Chengdu and is expected to create more than 600 professional posts by the end of 2026. It will integrate digitalization and big‑data analytics for clinical trials while broadening operational functions beyond pure R&D.
Chengdu was chosen for its thriving biopharmaceutical ecosystem, strong talent pool, and vibrant innovation environment. The centre will support Sanofi’s specialty‑care and vaccine businesses, aligning with China’s Healthy China 2030 initiative.
Sanofi has operated in China since 1982, and this expansion is part of a broader strategy that includes a €1 billion insulin‑manufacturing project in Beijing and other global hubs in India, Hungary, Malaysia, Colombia, and Spain.
The new centre strengthens Sanofi’s presence in a key growth market, enabling faster drug development and delivery and positioning the company to leverage local resources for innovation and operational efficiency.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.